Our guide on managing semaglutide bloating has additional strategies
Kang, S., Pinault, M., Pfefferle, L
Even light walking plus 23 days of simple strength work per week can make a meaningful difference when combined with GLP-1 therapy
Some possible healthcare-related risks of obesity include: Type 2 diabetes Heart disease and heart attacks Arthritis Gallbladder and fatty liver disease High cholesterol and high blood pressure Circulation problems and increase risks for stroke Infertility Osteoarthritis, in particular, the knees Sleep apnea and other breathing problems Certain kinds of cancer endometrial, breast, and colon Strain on bones, joints, and muscles due to increased weight Mobility issues Metabolic syndrome Emotional issues kidney disease and many others Semaglutide May Also Decrease Cardiometabolic Risks in Obese Patients Some medical experts predict that if obesity cases continue to rise, research has shown over the past three decades in the U.S., up to 50% of the population may be diagnosed with obesity by the year 2030

Ecological momentary assessment and cue-elicited drug craving as primary endpoints: study protocol for a randomized, double-blind, placebo-controlled clinical trial testing the efficacy of a GLP-1 receptor agonist in opioid use disorder
Magistrelli L, Comi C